Old Web
English
Sign In
Acemap
>
authorDetail
>
Y. Gong
Y. Gong
Novartis
Physical therapy
Medicine
Secukinumab
Internal medicine
in patient
3
Papers
64
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
OP0063 Canakinumab treatment in patients with colchicine-resistant FMF (CRFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40
2017
Annals of the Rheumatic Diseases
F De Benedetti
Marco Gattorno
Joost Frenkel
I. Calvo
Michel Moutschen
Pierre Quartier
Ozgur Kasapcopur
Seza Ozen
Ahmet Gül
Jordi Anton
I. Koné-Paut
Helen J. Lachmann
H. Hoffman
Eldad Ben-Chetrit
Andrew Zeft
Y. Gong
E. Vritzali
G Junge
Show All
Source
Cite
Save
Citations (1)
SAT0410 Secukinumab Improves Physical Function and Quality of Life in Patients with Active Ankylosing Spondylitis: 2-Year Data from Measure 1, A Phase 3 Randomised Trial
2016
Annals of the Rheumatic Diseases
Paul Emery
Dominique Baeten
Atul Deodhar
A. Wei
Piet Geusens
Zsolt Talloczy
Y. Gong
Brian Porter
Show All
Source
Cite
Save
Citations (2)
Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
2015
British Journal of Dermatology
Diamant Thaçi
J. Humeniuk
Y. Frambach
R Bissonnette
J.J. Goodman
S. Shevade
Y. Gong
Charis Papavassilis
Show All
Source
Cite
Save
Citations (61)
1